Source comparison
Comparison: TB-500 vs Other Regenerative Peptides — Cycling Strategies
TB-500 7–10 days Twice weekly 4–6 weeks at 2.0–2.5mg 4–8 weeks at 1.0–2.0mg weekly No receptor binding. Modulates intracellular actin Longer phases required to complete collagen remodelling; don't cycle like short-acting peptides BPC-157 <4 hours Daily or twic
This comparison does not assign a generated winner or score.
- TB-500
- 7–10 days
- Twice weekly
- 4–6 weeks at 2.0–2.5mg
- 4–8 weeks at 1.0–2.0mg weekly
- No receptor binding. Modulates intracellular actin
- Longer phases required to complete collagen remodelling; don't cycle like short-acting peptides
- BPC-157
- <4 hours
- Daily or twice daily
- 2–4 weeks at 250–500mcg
- Rarely used; compound clears rapidly
- Possible interaction with VEGF and dopamine pathways; no confirmed receptor
- Short cycles effective; rapid clearance means breaks between cycles are brief
- GHK-Cu
- 30 minutes (copper complex)
- Daily
- 4–8 weeks at 1–3mg
- Not typically maintained beyond loading
- Modulates metalloproteinases and TGF-beta; no receptor downregulation
- Very short half-life; applied topically or injected daily; cycling based on inflammation response, not pharmacokinetics
- Ipamorelin (GHRP)
- 2 hours
- Multiple daily doses
- 8–12 weeks
- 4–8 weeks at reduced frequency
- Growth hormone secretagogue receptor; desensitisation occurs with continuous use
- Requires strategic dosing windows to avoid receptor desensitisation; true cycling essential